Drugs / TEBITOREXANT
TEBITOREXANT
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04713930 | Jan → May 2021 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT03649997 | Aug → Dec 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03593954 | Jul → Sep 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03007693 | Jan → Oct 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02812251 | Jul → Nov 2016 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04080752 | Sep 2019 → Sep 2021 | mixed anxiety and depressive disorder | Janssen Research & Development, LLC | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEBITOREXANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802293 ↗ |
| Known as | JNJ-61393215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03007693 ↗ |
| Known as | tebideutorexant | “Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with...” PMID 40215570 ↗ Apr 2025 |
| Action | Inhibit | “a selective orexin-1 receptor antagonist” PMID 40215570 ↗ Apr 2025 |
| Modality | Small molecule | — CHEMBL4802293 ↗ |
| Route | Oral | “will be administered as an oral suspension.” NCT02812251 ↗ |